外周血造血干细胞移植治疗恶性血液病21例报告

目的：观察外周血造血干细胞移植（PBHSCT）治疗恶性血液病的疗效和并发症。方法：21例恶性血液病中8例行自体PBHSCT（auto-PBHSCT）,13例行异基因PBHSCT（allo-PBHSCT）。结果：21例全部获得造血重建,随访7～42月,10例（47.6%）存活,其中：auto-PBHSCT 5例,allo-PBHSCT5例。11例（52.4%）死亡,其中：auto-PBHSCT：3例复发死亡;allo-PBHSCT：5例复发死亡,2例移植相关死亡,1例死于第二肿瘤。结论：PBHSCT是治疗恶性血液病的有效方法,但如何有效减少复发、提高长期无病生存率需要进一步研究。

Peripheral blood hematopoietic stem cell transplantation in twenty-one patients with malignant hematological disease

Objective:To investigate the clinical efficacy and complication of peripheral hematopoietic blood stem cell transplantation(PBHSCT) in 21 patients with malignant hematological disease.Methods: Twenty-one patients with malignant hematological disease received PBHSCT,including 8 cases of auto-PBHSCT,13 cases of allo-PBHSCT.Results:The median follow-up duration was 7 to 42 months.Ten cases(47.6%) of all were alive,including 5 cases of auto-PBHSCT,5 cases of allo-PBHSCT.Eleven patients(52.4%) died,including 3 cases of auto-PBHSCT died from relapse,5 cases of allo-PBHSCT died from relapse,and 2 cases died from transplantation related mortality(TRM),and 1 case died from the second tumor.Conclusion:PBHSCT has a good efficacy in the treatment of malignant hematological disease and can enhance the disease-free survival.